Search - tctmd.com

Displaying 21 - 40 of 610

Sort: Relevancy | Date

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Presenter: Angelo Oliva

October 26, 2025

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Caitlin E. Cox

August 29, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Body Fat Distribution Influences Cardiovascular Age

Todd Neale

August 22, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

L.A. McKeown

June 12, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

Advertisement

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

ACC: It’s Time for Clinicians to Address Inflammation in CVD

CVD Still the Leading Cause of Death and Disease Globally

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Evolocumab Gains Expanded Indication for Primary Prevention

Body Fat Distribution Influences Cardiovascular Age

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content